Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy

Christopher Ryan, Dezheng Huo, James W. Stallings, Ronald L. Davis, Tomasz (Tom) Beer, Laura T. McWhorter

    Research output: Contribution to journalArticle

    37 Citations (Scopus)

    Abstract

    Objectives: Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD) and increased fracture risk. We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial. Methods: A total of 120 patients with prostate cancer and without bone metastases who had been treated with ADT for less than 12 months were enrolled in a clinical trial of zoledronic acid versus placebo. BMD measurements of the femoral neck, total hip, and lumbar spine were obtained before starting the study treatment by dual energy x-ray absorptiometry. The subjects answered a questionnaire regarding possible osteoporosis risk factors, including dairy product use, caffeinated beverage use, smoking history, alcohol intake, calcium/vitamin D supplementation, thyroid medication, and exercise. Results: The median duration of ADT was 3 months (range 0 to 12). Osteopenia or osteoporosis (T score of less than -1) was detected in two thirds of the subjects at one or more measured sites. The mean baseline BMD Z scores were femoral neck -0.091 ± 0.959, total hip 0.122 ± 1.005, and lumbar spine 0.657 ± 1.789. On multiple linear regression analysis, the duration of ADT was negatively associated with the Z score at all three sites and the body mass index, calcium/vitamin D supplementation, and alcohol use were positively associated with the Z score. Conclusions: BMD loss is a function of the duration of ADT during the first year of therapy. The body mass index, calcium/vitamin D supplementation, and alcohol use were associated with greater BMD, even after controlling for ADT exposure.

    Original languageEnglish (US)
    Pages (from-to)122-126
    Number of pages5
    JournalUrology
    Volume70
    Issue number1
    DOIs
    StatePublished - Jul 2007

    Fingerprint

    Bone Density
    Androgens
    Life Style
    Prostatic Neoplasms
    Vitamin D
    Bone Neoplasms
    zoledronic acid
    Femur Neck
    Alcohols
    Therapeutics
    Calcium
    Osteoporosis
    Hip
    Spine
    Body Mass Index
    Implosive Therapy
    Neoplasm Metastasis
    Dairy Products
    Metabolic Bone Diseases
    Beverages

    ASJC Scopus subject areas

    • Urology

    Cite this

    Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy. / Ryan, Christopher; Huo, Dezheng; Stallings, James W.; Davis, Ronald L.; Beer, Tomasz (Tom); McWhorter, Laura T.

    In: Urology, Vol. 70, No. 1, 07.2007, p. 122-126.

    Research output: Contribution to journalArticle

    @article{e58a8b13fb4b421da43d394ee025f49d,
    title = "Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy",
    abstract = "Objectives: Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD) and increased fracture risk. We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial. Methods: A total of 120 patients with prostate cancer and without bone metastases who had been treated with ADT for less than 12 months were enrolled in a clinical trial of zoledronic acid versus placebo. BMD measurements of the femoral neck, total hip, and lumbar spine were obtained before starting the study treatment by dual energy x-ray absorptiometry. The subjects answered a questionnaire regarding possible osteoporosis risk factors, including dairy product use, caffeinated beverage use, smoking history, alcohol intake, calcium/vitamin D supplementation, thyroid medication, and exercise. Results: The median duration of ADT was 3 months (range 0 to 12). Osteopenia or osteoporosis (T score of less than -1) was detected in two thirds of the subjects at one or more measured sites. The mean baseline BMD Z scores were femoral neck -0.091 ± 0.959, total hip 0.122 ± 1.005, and lumbar spine 0.657 ± 1.789. On multiple linear regression analysis, the duration of ADT was negatively associated with the Z score at all three sites and the body mass index, calcium/vitamin D supplementation, and alcohol use were positively associated with the Z score. Conclusions: BMD loss is a function of the duration of ADT during the first year of therapy. The body mass index, calcium/vitamin D supplementation, and alcohol use were associated with greater BMD, even after controlling for ADT exposure.",
    author = "Christopher Ryan and Dezheng Huo and Stallings, {James W.} and Davis, {Ronald L.} and Beer, {Tomasz (Tom)} and McWhorter, {Laura T.}",
    year = "2007",
    month = "7",
    doi = "10.1016/j.urology.2007.03.026",
    language = "English (US)",
    volume = "70",
    pages = "122--126",
    journal = "Urology",
    issn = "0090-4295",
    publisher = "Elsevier Inc.",
    number = "1",

    }

    TY - JOUR

    T1 - Lifestyle Factors and Duration of Androgen Deprivation Affect Bone Mineral Density of Patients with Prostate Cancer During First Year of Therapy

    AU - Ryan, Christopher

    AU - Huo, Dezheng

    AU - Stallings, James W.

    AU - Davis, Ronald L.

    AU - Beer, Tomasz (Tom)

    AU - McWhorter, Laura T.

    PY - 2007/7

    Y1 - 2007/7

    N2 - Objectives: Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD) and increased fracture risk. We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial. Methods: A total of 120 patients with prostate cancer and without bone metastases who had been treated with ADT for less than 12 months were enrolled in a clinical trial of zoledronic acid versus placebo. BMD measurements of the femoral neck, total hip, and lumbar spine were obtained before starting the study treatment by dual energy x-ray absorptiometry. The subjects answered a questionnaire regarding possible osteoporosis risk factors, including dairy product use, caffeinated beverage use, smoking history, alcohol intake, calcium/vitamin D supplementation, thyroid medication, and exercise. Results: The median duration of ADT was 3 months (range 0 to 12). Osteopenia or osteoporosis (T score of less than -1) was detected in two thirds of the subjects at one or more measured sites. The mean baseline BMD Z scores were femoral neck -0.091 ± 0.959, total hip 0.122 ± 1.005, and lumbar spine 0.657 ± 1.789. On multiple linear regression analysis, the duration of ADT was negatively associated with the Z score at all three sites and the body mass index, calcium/vitamin D supplementation, and alcohol use were positively associated with the Z score. Conclusions: BMD loss is a function of the duration of ADT during the first year of therapy. The body mass index, calcium/vitamin D supplementation, and alcohol use were associated with greater BMD, even after controlling for ADT exposure.

    AB - Objectives: Androgen deprivation therapy (ADT) is associated with loss of bone mineral density (BMD) and increased fracture risk. We sought to examine the impact of ADT and lifestyle variables on BMD in 120 patients with prostate cancer without bone metastases entering a randomized clinical trial. Methods: A total of 120 patients with prostate cancer and without bone metastases who had been treated with ADT for less than 12 months were enrolled in a clinical trial of zoledronic acid versus placebo. BMD measurements of the femoral neck, total hip, and lumbar spine were obtained before starting the study treatment by dual energy x-ray absorptiometry. The subjects answered a questionnaire regarding possible osteoporosis risk factors, including dairy product use, caffeinated beverage use, smoking history, alcohol intake, calcium/vitamin D supplementation, thyroid medication, and exercise. Results: The median duration of ADT was 3 months (range 0 to 12). Osteopenia or osteoporosis (T score of less than -1) was detected in two thirds of the subjects at one or more measured sites. The mean baseline BMD Z scores were femoral neck -0.091 ± 0.959, total hip 0.122 ± 1.005, and lumbar spine 0.657 ± 1.789. On multiple linear regression analysis, the duration of ADT was negatively associated with the Z score at all three sites and the body mass index, calcium/vitamin D supplementation, and alcohol use were positively associated with the Z score. Conclusions: BMD loss is a function of the duration of ADT during the first year of therapy. The body mass index, calcium/vitamin D supplementation, and alcohol use were associated with greater BMD, even after controlling for ADT exposure.

    UR - http://www.scopus.com/inward/record.url?scp=34447559432&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=34447559432&partnerID=8YFLogxK

    U2 - 10.1016/j.urology.2007.03.026

    DO - 10.1016/j.urology.2007.03.026

    M3 - Article

    C2 - 17656221

    AN - SCOPUS:34447559432

    VL - 70

    SP - 122

    EP - 126

    JO - Urology

    JF - Urology

    SN - 0090-4295

    IS - 1

    ER -